With Huge Debts And Divestment Plans, Wockhardt Chairman Habil Khorakiwala Exhorts Employees To Rise To The Challenge
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - These are tough times for Habil Khorakiwala, chairman of Wockhardt, one of India's largest pharmaceutical and biotechnology companies, as he deals with the worst financial crisis that any large Indian drug company has faced in the aftermath of the global economic meltdown
You may also be interested in...
Brakes May Be Put On Direct MNC Deals In India As Government Fears Threat To The Indian Drug Industry
MUMBAI - Acquisition of growing Indian firms by global pharmaceutical companies may get tough in the coming days as the government is brainstorming about how to clamp restrictions on buying controlling equity stakes in Indian entities through the automatic foreign direct investment route (FDI)
Brakes May Be Put On Direct MNC Deals In India As Government Fears Threat To The Indian Drug Industry
MUMBAI - Acquisition of growing Indian firms by global pharmaceutical companies may get tough in the coming days as the government is brainstorming about how to clamp restrictions on buying controlling equity stakes in Indian entities through the automatic foreign direct investment route (FDI)
Buzz Of Bids By GSK, Sanofi And Merck Get Louder As Piramal, Wockhardt Decline Sell-Off Talks
MUMBAI - Despite repeated denials, market buzz is getting louder that India's Piramal Healthcare is engaged in preliminary negotiations with multinational drug companies like GlaxoSmithKline, Sanofi-Aventis and Merck for a potential sell off